In multiple pre-clinical models of substance abuse and anxiety, ALDH2 inhibition prevents dopamine surge without changes to basal dopamine levels, and

  • Prevents substance relapse
  • Reduces binge eating
  • Reduces anxiety

Stimuli --> DA Surge --> Craving

ALDH2 Inhibition: Published Neurobiologic Model of Addiction and Mechanism of Action  

  • ALDH2 receptor research started at Harvard
  • CVT synthesized initial compounds (2009 Gilead acquires CVT)
  • Gilead invented GS-6637 (ANS-6637), a highly selective and reversible ALDH2-inhibitor
  • Composition of matter IP thru 2032+
  • Comprehensive manufacturing process and pre-clinical development
  • Preclinical efficacy in gold standard models of addiction relapse, anxiety and binge eating
  • Phase-1 studies in 99 human subjects (2013-2015)
  • Amygdala acquires ANS-6637 asset and initiates Phase-1b study (2017) 

MOA published in Nature Medicine

ALDH2 inhibition prevents pathophysiologic dopamine surges and associated craving without changes to basal dopamine

Stimuli --> DA Surge --> Craving

ALDH2 Inhibition: Published Pre-Clinical Efficacy Data

ANS-6637 Prevents Dopamine Surge Common to All Addiction


ANS-6637 is highly selective ALDH2 Inhibitor that prevents pathophysiologic dopamine surge and associated craving without changes to basal dopamine. This profile, which prevents craving and drug seeking behavior, has the potential to be used as pharmacotherapy for any substance and behavior based addiction.


Dopamine surge is in the brain is part of the reward circuity and common to all addiction.

Addiction hijacks the reward circuit to create pathophysiologic surges​​.

X        X